These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 32241284)
1. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit. Bertero L; Spadi R; Osella-Abate S; Mariani S; Castellano I; Gambella A; Racca P; Morino M; Cassoni P World J Surg Oncol; 2020 Apr; 18(1):65. PubMed ID: 32241284 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort. Rouyer M; François E; Cunha AS; Monnereau A; Noize P; Robinson P; Droz-Perroteau C; Le Monies de Sagazan A; Jové J; Lassalle R; Moore N; Fourrier-Réglat A; Smith D; Clin Colorectal Cancer; 2018 Jun; 17(2):129-139. PubMed ID: 29523416 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309 [TBL] [Abstract][Full Text] [Related]
4. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311 [TBL] [Abstract][Full Text] [Related]
5. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428 [TBL] [Abstract][Full Text] [Related]
6. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients. Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491 [TBL] [Abstract][Full Text] [Related]
7. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653 [TBL] [Abstract][Full Text] [Related]
8. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. Song A; Eo W; Lee S World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients. Daitoku N; Miyamoto Y; Sakamoto Y; Tokunaga R; Hiyoshi Y; Nagai Y; Iwatsuki M; Iwagami S; Yoshida N; Baba H Int J Clin Oncol; 2020 Apr; 25(4):651-659. PubMed ID: 31834556 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ishihara S; Hayama T; Yamada H; Nozawa K; Matsuda K; Miyata H; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Hashiguchi Y; Sugihara K; Watanabe T Ann Surg Oncol; 2014 Sep; 21(9):2949-55. PubMed ID: 24763981 [TBL] [Abstract][Full Text] [Related]
11. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080 [TBL] [Abstract][Full Text] [Related]
14. Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis. Kuo IM; Huang SF; Chiang JM; Yeh CY; Chan KM; Chen JS; Yu MC World J Surg Oncol; 2015 Mar; 13():92. PubMed ID: 25889950 [TBL] [Abstract][Full Text] [Related]
15. [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma]. Sevčíková K; Ušáková V; Bartošová Z; Sabol M; Ondrušová M; Ondruš D; Spánik S Klin Onkol; 2014; 27(1):38-44. PubMed ID: 24635436 [TBL] [Abstract][Full Text] [Related]
16. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. Demircan NC; Dane F; Ozturk MA; Babacan NA; Besiroglu M; Kaya S; Ercelep O; Tanrikulu E; Halil S; Koca S; Alan O; Hasanov R; Yumuk PF J BUON; 2019; 24(4):1494-1500. PubMed ID: 31646797 [TBL] [Abstract][Full Text] [Related]
17. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort. Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A; Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481 [TBL] [Abstract][Full Text] [Related]
18. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life. Gouverneur A; Bezin J; Jové J; Bosco-Lévy P; Fourrier-Réglat A; Noize P J Am Geriatr Soc; 2019 May; 67(5):913-919. PubMed ID: 30840323 [TBL] [Abstract][Full Text] [Related]
19. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival? Lau JWL; Chang HSY; Lee KY; Gwee YX; Lee WQ; Chong CS ANZ J Surg; 2018 Nov; 88(11):E772-E777. PubMed ID: 29938886 [TBL] [Abstract][Full Text] [Related]
20. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]